When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HSTO - Histogen concludes dosing in mid-stage study of HST-001 for baldness
Histogen Inc.
Histogen (HSTO) has completed patient dosing for the week 6 treatment timepoint in its Phase 1b/2a trial of HST-001 for the treatment of androgenic alopecia (pattern baldness) in men.
More news on: Histogen Inc., Healthcare stocks news,